Since the last time I wrote about immunology treatment provider AbbVie Inc. (NYSE: ABBV ) in April, its price hasn't moved much at all, with sub-2% gains. But short-term gains weren't the impetus behind the Buy rating on the stock anyway. It wasManika is a macroeconomist with over 20 years of experience in industries including investment management, stock broking, investment banking. She also runs the profile Long Term Tips [LTT], which focuses on the generational opportunity in the green economy. Her inves ...

Key Takeaways ABBV's neuroscience franchise is expected to generate $2.5 billion in Q2, up 15% year over year. Growth likely driven by Botox Therapeutic, Vraylar and market share gains for Qulipta and Ubrelvy. Newly launched Vyalev may contribute modest U.S. sales, with most revenues from international markets.AbbVie (ABBV) holds a leadership position in the neuroscience space, which encompasses blockbuster medications such as Botox Therapeutic and depression drug Vraylar. Over the years, the company has ...

June ultimately proved to be a very sour month for the Dividend Kings, with the 55 of them collectively posting a 0.39% loss. Meanwhile, the SPDR S&P 500 Trust ETF (I have a masters degree in Analytics from Northwestern University and a bachelors degree in Accounting. I have worked in the investment arena for over 10 years starting as an analyst and working my way up to a management role. Dividend investing is a personal hobby and I look forward to sharing my thoughts with the Seeking Alpha community.Analys ...

July 18, 2025 02:21 PM GMT Biopharma | North America A picture is worth a thousand words Comprehensive US drug market analysis (IQVIA Rx). The latest weekly Total Prescription YoY growth (wk ending 7/11) was +4.0% vs. +3.4% last wk and +2.5% over the past 12 wks. For week ended Jul 11, US total market weekly TRx YoY change was +4.0% vs. +1.8% year ago ( Exhibit7 ). Rolling 4-week TRx YoY was +3.0% and rolling 12-week TRx YoY was +2.5%. Extended unit (EUTRx) weekly YoY growth was +3.3%, below TRx YoY ( Exhib ...

高收入DIY投资组合服务 - 该服务主要目标是为投资者提供高收入、低风险且保本的投资策略，帮助DIY投资者构建稳定的长期被动收入组合[1] - 服务包含7种投资组合策略：3种买入持有型、3种轮动型以及3-Bucket NPP保守模型组合，涵盖高收益组合、股息增长组合及低回撤高增长组合[1] - 目标用户群体为收入型投资者（包括退休或临近退休人群），通过资产配置策略实现可持续收益[1] 投资组合构成 - 高收益组合包含两类：一类聚焦当期高收入资产，另一类采用股息增长投资(DGI)策略[1] - NPP模型组合采用保守策略，特点是低回撤与高增长特性相结合，适合风险厌恶型投资者[1] - 提供两周免费试用期供潜在用户验证策略有效性[1] 股票持仓披露 - 分析师披露其长期持仓涉及多个行业龙头，包括医疗保健(ABT ABBV JNJ)、消费品(KO PEP PG)、能源(CVX XOM)、科技(AAPL MSFT)及房地产投资信托(O NNN)等[2] - 持仓形式涵盖股票、期权及其他衍生品，但明确声明提及股票不构成投资建议[2] （注：文档3和文档4内容为免责声明与披露条款，根据任务要求已过滤）

It has been a volatile year for the U.S. markets, with many stocks experiencing impressive highs and sharp lows. Investing in such a turbulent environment may feel daunting for retail investors.However, dividend-paying stocks can help generate substantial passive income even amid market fluctuations. With the correct picks, investors can generate a steady dividend income even with a relatively modest investment. For instance, investing $2,000 each in Verizon Communications (VZ -0.45%), AT&T (T -0.28%), and ...

股息增长股票投资策略 - 股息增长股票通常不是最引人注目的投资选择 它们往往不会成为头条新闻 也不是短期内涨幅最大的股票 [1] - 该投资策略专注于提供高质量且可靠的股息增长投资理念 旨在为投资者构建持续增长的收益 [1] - 特别关注行业内的领先企业 以提供稳定性和长期财富创造 [1] 投资服务内容 - 提供投资组合、观察清单和实时聊天功能 会员可优先获取所有出版物和独家文章 [2] - 服务包含期权写作策略建议 以进一步提升投资者的收益 [1]

EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your ...

股价表现 - 公司最新收盘价为190 58美元 单日涨幅2 25% 超过标普500指数0 32%的涨幅 [1] - 过去一个月股价上涨0 49% 表现优于医疗行业3 4%的跌幅 但落后于标普500指数4 51%的涨幅 [1] 财报预期 - 预计2025年7月31日发布财报 分析师预测每股收益3 02美元 同比增长13 96% [2] - 季度收入预计为150 4亿美元 同比增长3 97% [2] - 全年每股收益预期12 07美元 同比增长19 27% 全年收入预期601 2亿美元 同比增长6 72% [3] 估值指标 - 公司当前远期市盈率为15 44倍 高于行业平均14 02倍 [6] - 当前PEG比率为1 23倍 与大型制药行业平均水平持平 [7] 分析师评级 - Zacks综合EPS预估在过去一个月下降2 29% [5] - 公司当前Zacks评级为3级(持有) [5] 行业地位 - 大型制药行业在Zacks行业排名中位列第62名 处于前26%分位 [8] - 该行业属于医疗板块 历史数据显示排名前50%的行业表现优于后50%约2倍 [8]

肿瘤产品线扩张 - 公司肿瘤产品线从最初聚焦于两种血液癌症药物Imbruvica和Venclexta扩展到包含实体瘤的五种疗法 新增Epkinly(淋巴瘤)、Elahere(卵巢癌)和Emrelis(肺癌) [1] - 肿瘤部门收入占第一季度总营收12% 同比增长6% [1] - 预计第二季度肿瘤部门总销售额16亿美元 同比下滑2% 主要因Imbruvica面临新型口服疗法竞争持续下滑 抵消了Venclexta、Epkinly和Elahere的增长贡献 [2][7] 免疫学产品线关注度 - 投资者更关注公司免疫学产品线 包括Humira、Rinvoq和Skyrizi三款旗舰药物 市场将重点关注其环比增长幅度和市场份额变化 [3] 肿瘤领域竞争格局 - 阿斯利康肿瘤部门收入占总营收41% 第一季度销售额同比增长13% 主要驱动力为Tagrisso、Lynparza等药物 [4] - 默克Keytruda单药占其总营收46% 与阿斯利康合作销售的Lynparza也是重要产品 [5] - 辉瑞第一季度肿瘤收入增长7% 占集团总营收27% 主要依靠Xtandi、Lorbrena等药物 [5] 估值与财务预测 - 公司股价表现优于行业平均水平 当前市盈率1421倍 略低于行业平均1516倍 [8] - 2025年EPS预估从1228美元下调至1208美元 但2026年EPS预估从1405美元微升至1406美元 [10]